Kidney Transplant Rejection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Kidney Transplant Rejection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Report Format: PDF+Excel | Report ID: SR112024A22239
Buy Now

The kidney transplant rejection market has been comprehensively analyzed in IMARC's new report titled "Kidney Transplant Rejection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Kidney transplant rejection occurs when the body's immune system recognizes the transplanted kidney as foreign and attacks it. This condition can develop despite efforts to match the donor and recipient tissue types and to suppress the immune system. The indications of rejection can vary but may include fever, decreased urine output, swelling or tenderness around the transplant site, and an increase in blood pressure. In more severe cases, there may be pain or discomfort in the area of the transplanted kidney, flu-like symptoms, and a decrease in kidney function, leading to a rise in creatinine levels in the blood. The diagnosis of the ailment typically involves regular monitoring of kidney function through blood tests to measure levels of creatinine and other markers, as well as imaging tests, such as ultrasounds or biopsies, to assess the health of the transplanted kidney tissue.

The increasing incidence of abnormal immune response, which can cause the body's innate system to recognize the transplanted kidney as foreign tissue, is primarily driving the kidney transplant rejection market. In addition to this, the inflating utilization of potent immunosuppressive medications, including calcineurin inhibitors, corticosteroids, and antimetabolites, aimed at suppressing the immune response and prolonging graft survival, is creating a positive outlook for the market. Moreover, the widespread adoption of innovative therapies, such as monoclonal antibodies targeting specific immune cells or pathways involved in rejection, is also bolstering the market growth. Apart from this, the rising prevalence of complementary approaches like plasmapheresis and intravenous immunoglobulin therapy to modulate immune responses and mitigate rejection episodes in patients is acting as another significant growth-inducing factor. Additionally, the emerging popularity of regenerative medicine that encompasses strategies to induce immune tolerance or regenerate damaged tissues in individuals suffering from the condition is further propelling the market growth. Besides this, the escalating application of novel technologies, such as organ perfusion systems, which facilitate ex vivo organ preservation and optimization before transplantation in order to mitigate rejection risks and enhance transplant success rates, is expected to drive the kidney transplant rejection market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the kidney transplant rejection market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for kidney transplant rejection and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the kidney transplant rejection market in any manner.

Time Period of the Study

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034
     

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the kidney transplant rejection market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the kidney transplant rejection market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs

Competitive Landscape

This report also provides a detailed analysis of the current kidney transplant rejection marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance    
     

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     
Drugs Company Name
Envarsus XR (Tacrolimus extended-release) Veloxis Pharmaceuticals
Nulojix (Belatacept) Bristol-Myers Squibb
Rapamune (Sirolimus) Pfizer
Zortress (Everolimus) Novartis
AT-1501 Eledon Pharmaceuticals
MDR-101 Medeor Therapeutics
TX200-TR101 Sangamo therapeutics
VIB4920 Horizon Therapeutics
Clazakizumab CSL Behring


*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report

Key Questions Answered in this Report

Market Insights

  • How has the kidney transplant rejection market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
  • What was the country-wise size of the kidney transplant rejection market across the seven major markets in 2023 and what will it look like in 2034?
  • What is the growth rate of the kidney transplant rejection market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?
     

Epidemiology Insights

  • What is the number of prevalent cases (2018-2034) of kidney transplant rejection across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of kidney transplant rejection by age across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of kidney transplant rejection by gender across the seven major markets?
  • How many patients are diagnosed (2018-2034) with kidney transplant rejection across the seven major markets?
  • What is the size of the kidney transplant rejection patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (2024-2034) across the seven major markets?
  • What are the key factors driving the epidemiological trend of kidney transplant rejection?
  • What will be the growth rate of patients across the seven major markets?
     

Kidney Transplant Rejection: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for kidney transplant rejection drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the kidney transplant rejection market?
  • What are the key regulatory events related to the kidney transplant rejection market?
  • What is the structure of clinical trial landscape by status related to the kidney transplant rejection market?
  • What is the structure of clinical trial landscape by phase related to the kidney transplant rejection market?
  • What is the structure of clinical trial landscape by route of administration related to the kidney transplant rejection market?

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Kidney Transplant Rejection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More